Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Kovsies shine at USSA Cross Country Championships
2009-10-15

Thandi Malindi (far left) from the UFS and two Matie athletes, Elene Lourens and Mia Pienaar.
Photo: Supplied

Kovsie cross-country athletes Boy Soke and Thandi Malindi were included in the USSA squad for 2010 at the World Student Cross-Country Championships in Canada. The final team will be announced after the SA Cross-Country Championships. They recently participated in the USSA Cross-Country Championships that were held at the University of Johannesburg. According to Mr DB Prinsloo from KovsieSport at the University of the Free State, the UFS team did extremely well at the recent USSA Cross-Country Championships.

Kovsies won the women long-race team competition (8 km), while the men came second in the men’s long-race team (10 km) competition. In the short-race team competitions (4 km for men and women) the UFS men finished fourth and women ended in fifth place respectively.

Thandi Malindi, the UFS Women Cross-Country captain, was the first Kovsie over the line (third place), followed by Nelmarie Loubser (4th) and Maryna Swanepoel (6th), who also won the team competition in the 8 km (long race) with 13 penalty points against the 14 penalty points of the Maties who finished second.

Mr DB Prinsloo from KovsieSport at the UFS praised the Kovsie athletes for the manner in which they ran the race. “Thandi gave her all; so much so that she had to be admitted to hospital due to dehydration. Nelmaré ran the hills with a smile on her face and Maryna, who suffered from low blood sugar, persevered until the end so that a Matie athlete could not pass her. You all showed to us what ‘vasbyt’ really means,” Mr Prinsloo said.

Kovsies performed above expectation in the short race (4 km) for women. “Our women finished fifth in the team competition. If one takes into consideration that the Kovsies were represented by 400/800 athletes, i.e. Elri Richter (400/800), who came seventh, Anneri Ebersohn (400/400 hurdles), who ended in sixteenth place and Yvonne Eyssen (heptathlon) who ended in twentieth place, it makes this performance even better,” Mr Prinsloo commented.

In the men’s short race (4 km) where the Kovsies were represented by young first-year 800 m athletes, the UFS did excellently by finishing in fourth place. Hanne Naudé (18th), Lebohang Mpure (19th), Abri Horak (26th) and Gerrit Viljoen (34st) ran their hearts out!

The long race (10 km) for men, which was run on an extremely difficult course, was another highlight – also for the Kovsies. The Kovsies finished second in the team competition. Boy Soke (4th), Windy Jonas (8th), Schadrach Mochelenyane (10th) en Michael Tlhoro (21st) represented the Kovsies with honours. Unfortunately Johan Cronjé and Dumisane Hlaselo had to withdraw from the race due to injuries.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept